Everest Organics Ltd. benchmarking: Perfomance to industry peers

Financial

	Everest Organics	Nectar Lifesciences	Haleos Labs
Operational Metrics
Pharmaceuticals
Manufacturing Capacity - Esomeprazole	144.0 MTPA	n/a	n/a
Capacity Utilization - Esomeprazole	65.34 %	n/a	n/a
Capacity Utilization - Benzimidazole	58.26 %	n/a	n/a
Capacity Utilization - Omeprazole	72.67 %	n/a	n/a
Realization - Pantaprazole Sodium	4701311.48 Rs/Tonne	n/a	n/a
Realization - Ammonium Sulphate	22104.75 Rs/Tonne	n/a	n/a
Realization - Esomeprazole Magnesium	4502659.15 Rs/Tonne	n/a	n/a
Realization - Chloro Compound	2039819.1 Rs/Tonne	n/a	n/a
Manufacturing Capacity - Pantaprazole	60.0 MTPA	n/a	n/a
Realization - Omeprazole Powder	3218387.06 Rs/Tonne	n/a	n/a
Manufacturing Capacity - Benzimidazole	250.0 MTPA	n/a	n/a
Capacity Utilization - Chloro Compound	61.68 %	n/a	n/a
Realization - Benzimidazole	1270727.38 Rs/Tonne	n/a	n/a
Realization - Op. Sulphide	2949666.67 Rs/Tonne	n/a	n/a
Capacity Utilization - Pantaprazole	10.27 %	n/a	n/a
Manufacturing Capacity - Chloro Compound	480.0 MTPA	n/a	n/a
Realization - Tetralone	700000.0 Rs/Tonne	n/a	n/a
Manufacturing Capacity - Omeprazole	215.0 MTPA	n/a	n/a
R&D as a % of Total Sales	1.16 %	0.97 %	n/a
Financials
5 yr Average ROE	5.99 %	-3.66 %	9.86 %
5yr average Equity Multiplier	3.85	2.12	2.28
5yr Average Asset Turnover Ratio	0.99	0.73	0.85
5yr Avg Net Profit Margin	1.46 %	-2.27 %	4.95 %
Price to Book	6.32	0.66	1.96
P/E	69.28	0.0	21.66
5yr Avg Cash Conversion Cycle	-104.59 Days	88.68 Days	-6.07 Days
Inventory Days	70.24 Days	136.85 Days	78.84 Days
Days Receivable	188.66 Days	69.3 Days	56.81 Days
Days Payable	263.18 Days	116.07 Days	142.69 Days
5yr Average Interest Coverage Ratio	2.08	0.46	4.18
5yr Avg ROCE	11.9 %	3.29 %	11.01 %
5yr Avg Operating Profit Margin	5.27 %	5.36 %	10.73 %
5 yr average Debt to Equity	0.88	0.71	0.52
5yr CAGR Net Profit	n/a	9.19 %	8.2 %
5yr Average Return on Assets	2.03 %	-1.73 %	4.32 %
Shareholdings
Promoter Holding	59.64 %	44.91 %	71.41 %
Share Pledged by Promoters	0.0	98.77 %	0.0
Change in Promoter Holding (3 Yrs)	-14.51 %	-10.89 %	1.55 %
Change in Mutual Fund Holding (3 Yrs)	0.0	0.0	0.0

Business

	Everest Organics	Nectar Lifesciences	Haleos Labs
Product Wise Break-Up	Product Wise Break-Up Omeprazole Powder 35.93 Esomeprazole Magnesium 28.56 Fenofibrate 2.5 Pantaprazole Sodium 1.8 Rabeprazole 1.48 Dexlansoprazole 0.03 Oseltamivir 0 Tetralone 0 Ammonium Sulphate 0 Op. Sulphide 0 Chloro Compound 0 Benzimidazole 0 Drugs and Pharmaceuticals 0 API`S 0 Others 29.7	Product Wise Break-Up Esomeprazole Magnesium 0 API`S 0 Benzimidazole 0 Op. Sulphide 0 Rabeprazole 0 Tetralone 0 Pharmaceuticals 100.0 Ammonium Sulphate 0 Dexlansoprazole 0 Fenofibrate 0 Pantaprazole Sodium 0 Omeprazole Powder 0 Oseltamivir 0 Chloro Compound 0	Product Wise Break-Up Esomeprazole Magnesium 0 API`S 0 Benzimidazole 0 Op. Sulphide 0 Rabeprazole 0 Tetralone 0 Drugs and Pharmaceuticals 0 Ammonium Sulphate 0 Dexlansoprazole 0 Fenofibrate 0 Pantaprazole Sodium 0 Omeprazole Powder 0 Oseltamivir 0 Chloro Compound 0 Others 100
Segment Break-Up	Segment Break-Up Active Pharmaceutical Ingredient (API) 100.0	-	-
Location Wise Break-Up	Location Wise Break-Up India 83.02 Rest of the World 16.98	Location Wise Break-Up Rest of the World 38.61 India 61.39	Location Wise Break-Up Rest of the World 42.03 India 57.97
Raw Material Break-Up	Raw Material Break-Up 3, 5 Lutidine 48.05 Toluene 12.41 Acetone 10.81 Para Anisidine 9.48 MDC 786.60 7.13 APS 206.88 5.63 Acetic Acid 3.54 DMS 299.44 2.95 Others 0	-	-

Everest Organics Ltd.

Everest Organics Ltd.

Financial

Business

SIGN UP FOR FREE